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ABSTRACT
We prospectively evaluated the incidence of human herpesvirus 6 (HHV-6) DNAemia after allogeneic hema-
topoietic stem cell transplantation (HSCT) using quantitative plasma real-time polymerase chain reaction. Of
46 recipients of bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT) from related (n 
11) or unrelated donors (n  22), and cord blood transplantation (CBT) from unrelated donors (n  13), 22
(47.8%) developed HHV-6 DNAemia. HHV-6 DNA levels ranged from 200 to 200,000 copies/mL of plasma,
and HHV-6 DNAemia was observed significantly more frequently after CBT than after BMT/PBSCT (92.3%
vs 30.3%; P < .001). Multivariate analyses identified CBT (vs BMT/PBSCT), HLA mismatches between
recipient and donor, and low anti–HHV-6 IgG titer before transplantation as the only risk factors for
developing HHV-6 DNAemia. Three patients developed central nervous system (CNS) disorders with detect-
able HHV-6 DNA in the cerebrospinal fluid; all of these patients simultaneously developed HHV-6 DNAemia.
These results suggest that HHV-6 DNAemia is frequently observed after allogeneic HSCT, especially in
patients with the aforementioned risk factors. Thus, together with the assessment of risk factors, monitoring
of HHV-6 DNAemia could be a useful asset in diagnosing HHV-6–associated CNS disorders.
© 2007 American Society for Blood and Marrow Transplantation
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Human herpesvirus 6 (HHV-6), a member of the
etaherpesvirinae subfamily, has biological properties
imilar to those of cytomegalovirus (CMV) and
HV-7 [1,2]. After primary infection during early
hildhood, HHV-6 remains latent but may reactivate
n immunocompromised patients. Some 80%-90% of
dults have serum anti-human HHV-6 antibody or
etectable HHV-6 in peripheral blood mononuclear
ells (PBMCs) or saliva [3-6]. The incidence of c
00HV-6 reactivation has been reported to be 28%-
8% after hematopoietic stem cell transplantation
HSCT) [6-16]. Several retrospective studies have
emonstrated that the incidence of HHV-6 reactiva-
ion is higher after allogeneic cord blood stem cell
ransplantation (CBT) than after allogeneic bone mar-
ow transplantation (BMT) and/or peripheral blood
tem cell transplantation (PBSCT) [17,18]. HHV-6
eactivation has also been associated with skin rash,
ever, myelosuppression, and pneumonitis, and may
ause graft-versus-host disease (GVHD) [9-14,17-20].
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HHV-6 Reactivation after Allogeneic HSCT 101entral nervous system (CNS) disorders, such as en-
ephalitis, have also been linked to HHV-6, although
he causative relationship and incidence have not yet
een fully clariﬁed [8,12,21-24].
To elucidate the optimal management of
HV-6 reactivation and HHV-6 diseases after al-
ogeneic HSCT, we prospectively monitored
HV-6 DNA in plasma (HHV-6 DNAemia) using
uantitative real-time polymerase chain reaction
PCR). Through this prospective study, we identi-
ed several risk factors for developing HHV-6
NAemia, including pretransplantation anti–HHV-6
gG titers, which, to the best of our knowledge, has not
een reported previously. We believe that identifying
HV-6 DNAemia may be useful in detecting HHV-6–
ssociated CNS disorders.
ATIENTS AND METHODS
atients and Transplantation Procedures
A total of 46 patients undergoing allogeneic
SCT for hematologic malignancies at Keio Univer-
ity Hospital between July 2003 and May 2005 were
valuable for analysis. Patient characteristics are given
n Table 1. Eleven patients received BMT or PBSCT
rom a HLA-identical sibling (n  9) or HLA-mis-
able 1. Patient Characteristics
Total (n  46) rBM
ge, years
Median (range) 47 (20-63)
ex
Male/female 21/25
nderlying disease
Acute leukemia 25
Myelodysplastic syndrome 8
Myeloproliferative disease 4
Non-Hodgkin’s lymphoma 6
Multiple myeloma 3
onditioning regimen
Myeloablative 27
Reduced-intensity 19
LA disparity
Complete match 33
1 locus mismatch 3
2 locus mismatch 10
VHD prophylaxis
Cyclosporin A  methotrexate 10
Tacrolimus  methotrexate 36
HV-6 IgG titer*
<  40 13
>  40 25
retreatment CMV serologic status
Recipient  and/ or donor  43
Recipient /donor  3
MV reactivation
Positive 34
Negative 12
he CMV serologic status of the CBT donor was determined to b
HHV-6 IgG titer was examined in 38 patients.atched related donor (n  2) (rBMT/PBSCT), 22
atients received BMT from an unrelated donor
uBMT), and 13 patients received cord blood trans-
lantation (CBT) from an unrelated donor. The grafts
ere not manipulated ex vivo. The patients were condi-
ioned with either a myeloablative regimen, comprising
2 Gy of total body irradiation (TBI) or busulfan plus
yclophosphamide (Bu-Cy), or a reduced-intensity
egimen, comprising ﬂudarabine plus melphalan or
udarabine plus cyclophosphamide. For GVHD pro-
hylaxis, all but 1 recipients of uBMT and CBT re-
eived tacrolimus with or without methotrexate, and 9
f 11 recipients of rBMT/PBSCT received cyclospor-
ne A with or without methotrexate. HLA disparity
iffered signiﬁcantly among the 3 groups, including a
- or 2-locus mismatch in 11 of the 13 CBT recipients
Table 1).
Intravenous acyclovir, 750 mg/day, was admin-
stered from 3 days before transplantation until
osttransplantation day 14 for herpes simplex virus
rophylaxis. For CMV prophylaxis, patients were
onitored by CMV antigenemia assay or real-time
CR after neutrophil engraftment, and ganciclovir
r foscarnet were started preemptively when posi-
ive results of CMV antigenemia and/or real-time
CR were obtained, as reported previously [25,26].
T (n  11) uBMT (n  22) CBT (n  13) P Value
.82
3-59) 43.5 (31-61) 50 (20-63)
.59
/7 12/10 5/8
.29
6 11 8
3 3 2
0 4 0
0 3 3
2 1 0
.64
6 14 6
5 8 7
<.0001
9 22 2
1 0 2
1 0 9
<.0001
9 1 0
2 21 13
.44
2 8 3
9 11 5
.59
0 20 13
1 2 0
.62
8 15 11
3 7 2
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A. Yamane et al.102erologic Examination for HHV-6
A ﬂuorescent antibody method was used to detect
nti–HHV-6 antibody in serum. Brieﬂy, sera were ﬁrst
iluted 10 times, then serially diluted twofold in phos-
hate-buffered saline, after which they were reacted with
HV-6 antigen ﬁxed on a slide. HHV-6 antigen was
repared from NP40-solubilized lymphocytes infected
ith the virus. After incubation for 1 hour at 37°C, the
lides were washed and then reacted with ﬂuorescein
sothiocyanate–conjugated rabbit anti-human IgG anti-
ody (Dako, Glostrup, Denmark). Fluorescence was de-
ected by ﬂuorescent microscopy, and the endpoint titer
as determined as the reciprocal of the maximum dilu-
ion at which ﬂuorescence was detected. Titers  10
ere considered positive. Of the 38 patients examined,
ll but 1 were seropositive for HHV-6.
ample Collection and Real-Time PCR for HHV-6
Plasma samples were obtained weekly from post-
ransplantation week 1 to week 8 or until HHV-6
NA became undetectable by real-time PCR in pa-
ients who had exhibited positive PCR results. Three
atients failed to provide a blood sample during post-
ransplantation week 1 or 2. Cerebrospinal ﬂuid (CSF)
amples were also obtained when patients with posi-
ive results for HHV-6 DNA in plasma developed any
NS symptoms. The results of plasma real-time PCR
ere provided to each physician, and CNS symptoms
ere monitored daily as part of routine care. Real-
ime PCR was performed as reported previously
16,25-27]. Brieﬂy, DNA extracted from plasma using
QIAamp Blood Mini Kit (Qiagen, Valencia, CA) was
ubjected to PCR. Sequences of PCR primers and a
robe for HHV-6 variant A (HHV-6A) were selected
rom the U89 immediate-early protein region of
HV-6, and those for variant B (HHV-6B) were
elected from the U90 IE-A transactivator region.
he sequences of forward primers were 5=-GTACAG-
CTCAGTGACAGATCTG-3= for both HHV-6A
nd -6B; the reverse primers were 5=-AGGAACCA-
CTTGTTCTGTCCCTT-3= for HHV-6A and 5=-
GTCATACCAGGAAGCGTTTCG-3= for HHV-
B. The Taqman probe selected between the primers
as dual-labeled with FAM (6-carboxyﬂuorescein)
t the 5= end as a reporter dye and with TAMRA
6-carboxy-tetramethylrhodamine) at the 3= end as a
uenching dye, with a sequence of 5=-CAGCCCC-
ATAAAAGGTCACAGACAAAAGA-3=. The PCR
eaction was performed using TaqMan Universal
CR Master Mix (PE Biosystems, Foster City, CA),
nd nuclease degradation of the probe was detected as
n increase in ﬂuorescence intensity by an ABI
RISM 7700 (PE Biosystems). The quantiﬁcation of
HV-6 was carried out with a serially diluted stan-
ard ranging from 10 to 1  107 copies, and the gene
opy numbers were calculated by Sequence Detection System version 1.6.3 software (PE Biosystems). The
ensitivity of this assay was 200 copies/mL of plasma.
tatistical Analyses
Differences between the groups were assessed by
isher’s exact test, the Kruskal-Wallis test, and the
ann-Whitney U test as appropriate. The cumulative
ncidence of HHV-6 DNAemia was calculated ac-
ording to the Kaplan-Meier method, and compari-
ons were made using the log-rank test. Multivariate
nalysis was performed using the Cox proportional
azards model with stepwise regression, using the crite-
ia to remove factors with P values .10. P values .05
ere considered statistically signiﬁcant.
ESULTS
etection of HHV-6 DNA in Plasma
HHV-6 DNA in plasma became positive (HHV-6
NAemia) in at least one sample in 22 (47.8%) of 46
atients (Figure 1A). The detected HHV-6 strains
igure 1. (A) Cumulative incidence of the detection of HHV-6
NA in plasma (HHV-DNAemia) after allogeneic HSCT.
B) Cumulative incidence of HHV-6 DNAemia according to the
ources of stem cells: CBT, BMT, or PBSCT. HHV-6 DNAemia
as more frequently observed after CBT than after BMT/PB-
CT (P  .001).
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HHV-6 Reactivation after Allogeneic HSCT 103ere exclusively HHV-6B; HHV-6A was not detected
n any patients. The median time of the ﬁrst detection
f HHV-6 DNAemia was posttransplantation week 3
range, week 2-week 5). Of the 22 patients with
HV-6 DNAemia, 11 (50%) had 1 positive sample
nd the other 11 had 2 or more positive samples.
HV-6 DNA was more frequently detected in recip-
ents of CBT (92.3%) than in recipients of rBMT/
BSCT or uBMT (30.3%, P .001; Figure 1B). Only
of the 11 rBMT/PBSCT recipients developed
HV-6 DNAemia. Among the 22 patients with
HV-6 DNAemia, 4 had a second HHV-6 DNAemia
t posttransplantation week 7 or 8, deﬁned as a reac-
ivation after clearance of the ﬁrst reactivation.
lasma Levels of HHV-6 DNA
fter Transplantation
In patients with HHV-6 DNAemia, the number of
HV-6 DNA copies ranged from 200 to 200,000/mL
f plasma. The relationship between the time after
ransplantation and the HHV-6 DNA levels in plasma
igure 2. HHV-6 DNA levels in plasma after allogeneic HSCT.
pproximately 80% of positive samples and samples with high
HV-6 DNA copies ( 10,000 copies/mL) were distributed be-
ween weeks 2 and 4 after transplantation.
able 2. Factors Affecting HHV-6 DNAemia after Allogeneic Hemato
Factors Univariate
tem cell source
CBT versus BMT/PBSCT/uBMT <.0
cute GVHD
Grade 0-I versus II-IV .2
LA disparity
Complete match versus 1-2 locus mismatch .0
VHD prophylaxis
Tacrolimus versus cyclosporine A .0
HV-6 IgG titer*
<  40 versus >  40 .0
MV infection
Positive versus negative .0
he results of univariate analyses using the log-rank test and mult
regression method of factors affecting the cumulative incidence
I indicates conﬁdence interval; NS, not signiﬁcant.
HHV-6 IgG titer was examined in 38 patients.s shown in Figure 2. Twenty-nine of 36 (80.6%)
HV-6 DNA–positive samples and 4 of 5 (80%) sam-
les with high HHV-6 DNA copies ( 10,000 copies/
L) were distributed at posttransplantation weeks 2-4.
he median duration of HHV-6 DNAemia was 1.5
eeks (range, 1-3 weeks). The median maximum num-
er of HHV-6 DNA copies in each patient did not differ
igniﬁcantly between CBT recipients (750 copies/mL;
ange, 200-200,000 copies/mL) and rBMT/PBSCT or
BMT recipients (850 copies/mL; range, 200-40,000
opies/mL; P  .67). Two patients exhibited HHV-6
NAemia at posttransplantation week 8; subsequent
onitoring conﬁrmed clearance in both cases.
isk Factors for Developing HHV-6 DNAemia
The stem cell source signiﬁcantly affected the inci-
ence of HHV-6 DNAemia, as shown in Figure 1B. In
ddition, univariate analysis identiﬁed HLA mismatch
etween patient and donor, tacrolimus for GHVD pro-
ylaxis (vs cyclosporine A), lower anti–HHG-6 IgG titer
efore transplantation ( 40 vs  40), and CMV
eactivation as risk factors for developing HHV-6
NAemia (Table 2). Other factors, including age, sex,
nderlying diseases, conditioning regimen, and pre-
ransplantation CMV serologic status, had no signiﬁ-
ant effect on the incidence of HHV-6 DNAemia
data not shown). Among these factors, cord blood as
stem cell source, HLA mismatch, and low anti–
HV-6 IgG titer before transplantation remained as
igniﬁcant risk factors as identiﬁed by multivariate
nalysis (Table 2).
ssociation between CNS Disorders and HHV-6
NA in Plasma and CSF
Among our 46 patients, 4 (patients 30, 38, 39, and
5) manifested CNS symptoms and underwent CSF
tem Cell Transplantation
ue
Multivariate
Hazard Rate 95% CI P Value
132.096 7.029-2482.627 .001
— — —
0.039 0.002-0.667 .025
NS
3.550 1.177-10.705 .024
NS
analyses using the Cox proportional hazards model with stepwise
V-6 DNAemia are shown.poietic S
P Val
01
69
19
10
31
33
ivariate
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A. Yamane et al.104xamination. Patient 45 was diagnosed with bacterial
eningitis and did not exhibit HHV-6 DNA in
lasma or CSF at the onset, whereas HHV-6 DNA
as detected in CSF in the other 3 patients, at levels
anging from 200 to 600 copies/mL. In these 3 pa-
ients, CSF examination demonstrated no elevation of
eukocytes, along with normal levels of protein and
lucose. Cultures of CSF for bacteria and fungus were
egative. Magnetic resonance imaging of the brain
nd spinal cord revealed no abnormal ﬁndings, except
or a T2-weighted high-intensity, 1-cm lesion in the
eft frontal cortex in patient 30. CNS disorders due to
HV-6 were diagnosed in these 3 patients; these
atients’ characteristics and outcomes are summarized
n Table 3. Their neurologic symptoms included se-
erely impaired consciousness, headache, and dyses-
hesia. Although these patients were HHV-6 seropos-
tive before transplantation, they had low antibody
iters against HHV-6. Weekly monitoring detected
HV-6 DNAemia at the onset of CNS symptoms,
ith detection preceding the onset of CNS disorders
n only 1 patient (patient 39). All patients were treated
ith intravenous ganciclovir. The symptoms of pa-
ients 38 and 39 improved after intravenous ganciclo-
ir 10 mg/kg/day, ultimately achieving complete res-
lution, with HHV-6 DNA becoming undetectable in
oth plasma and CSF. Patient 30, in whom ganciclovir
as not initiated immediately after the onset of CNS
ymptoms, died without experiencing improvement in
hese symptoms.
elationship between HHV-6 DNAemia and
ntiviral Therapy for CMV Infection/Disease
Of the 34 patients with CMV reactivation, 27
eceived ganciclovir or foscarnet as preemptive ther-
py for CMV infection (n  25) or therapy for CMV
isease (n  2). In these patients, the median time of
he diagnosis of CMV infection or disease was post-
ransplantation week 6 (range, week 1-week 9), signif-
cantly later than the detection of HHV-6 DNAemia
P  .0001). Thirteen patients developed HHV-6
NAemia before initiation of antiviral therapy, whereas
nly 2 patients developed HHV-6 DNAemia after ini-
iation of antiviral therapy. The remaining 12 patients
able 3. Clinical Characteristics and Outcomes of Patients with HHV-
Patient
Stem Cell
Source
HHV-6
IgG* CNS Symptoms
30 UBMT 20 Impaired consciousness (3rd) 4
38 CBT 40 Headache (3rd) 2
39 CBT 20 Dysesthesia (3rd)
NS, central nervous system; HHV-6, human herpesvirus 6; CSF, c
transplantation from unrelated donor; GVHD, graft-versus-hos
Titers were determined before transplantation.
*Copies/mL. The parentheses indicate the posttransplantation week of thid not develop HHV-6 DNAemia during the study
eriod.
ISCUSSION
HHV-6 reactivation is often observed after allo-
eneic HSCT; however, its clinical signiﬁcance has
et to be fully elucidated. To clarify this issue, several
nvestigators have attempted to evaluate the incidence
f HHV-6 reactivation after allogeneic HSCT using
arious methods, including virus isolation, PCR, and
ntigenemia assays [6-16]. The reported incidence of
HV-6 reactivation after allogeneic HSCT varies
idely, ranging from 28% to 78% [6-15]. This signif-
cant variation may be explained by the sensitivity of
he tests used in each study. Another explanation
ould be the differences in the clinical samples sub-
ected to analysis (PBMCs or cell-free serum/plasma),
ecause PCR can detect latently infected HHV-6
NA in PBMCs, possibly leading to false-positive
esults. Therefore, in the present study, we investi-
ated HHV-6 DNAemia using cell-free plasma in
llogeneic HSCT recipients so that we could exclude
he detection of latent infection and further evaluate
he longitudinal viral load.
Twenty-two of 46 patients (47.8%) developed
HV-6 reactivation, with a signiﬁcantly higher rate
f reactivation in CBT recipients compared with
MT or PBSCT recipients. This ﬁnding is consistent
ith previous reports [17,18] and can be explained by
he absence of primed HHV-6–speciﬁc T cells and
he immunologic immaturity after CBT. In addition
o the stem cell sources, multivariate analyses also
dentiﬁed HLA mismatches between patient and do-
or and low anti–HHV-6 IgG titers before transplan-
ation as signiﬁcant factors associated with HHV-6
eactivation. Patient–donor HLA mismatches have
een reported to cause prolonged immune deﬁciency
fter allogeneic HSCT, which could contribute to
HV-6 reactivation [16,28].
The rate of HHV-6 DNAemia was signiﬁcantly
igher in patients with a lower anti–HHV-6 IgG
iter before transplantation compared with those
ated CNS Disorders
-6
a**
HHV-6
CSF** Treatment Outcome Complication
(3rd) 200 (3rd) Ganciclovir Death Liver failure
(3rd) 200 (3rd) Ganciclovir Improved Mild GVHD
(2nd) 600 (3rd) Ganciclovir Improved Moderate GVHD
pinal ﬂuid; CBT, cord blood transplantation; uBMT, bone marrow
se.6-Associ
HHV
Plasm
0,000
0,000
400
erebros
t diseae onset of CNS disorders or ﬁrst detection of HHV-6 DNA.
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HHV-6 Reactivation after Allogeneic HSCT 105ith higher titers. To the best of our knowledge, no
eport to date has shown the relationship between
retransplantation anti–HHV-6 antibody titer and
osttransplantation HHV-6 DNAemia. It is plausi-
le that the neutralizing and suppressing activity of
nti–HHV-6 IgG exerts an effect against HHV-6
eplication [29]. With respect to the pretransplan-
ation serologic status of HHV-6, the present study
ncluded 1 patient who was HHV-6 seronegative
efore transplantation. This patient developed
HV-6 DNAemia between posttransplantation
eeks 2 and 3; we speculated that transmission of
HV-6 through transplanted cord blood or trans-
used blood cells was the source of the HHV-6
NAemia in this patient [3,30,31].
In the present study, patients received acyclovir
ntil day 14 for the prophylaxis against herpes simplex
irus and were allowed to receive ganciclovir or fos-
arnet for CMV infection/disease. There is a possibil-
ty that these agents affected the incidence and clinical
ourse of HHV-6 DNAemia after HSCT. Acyclovir is
ess active against HHV-6, and ganciclovir and foscar-
et are potential antiviral agents for HHV-6. Thus,
hese drugs could have played a role in suppressing
HV-6 reactivation. Although 27 of 46 patients
58.7%) received ganciclovir or foscarnet for CMV
nfection/disease, the time of detection of HHV-6
NAemia (posttransplantation week 3) was signiﬁ-
antly earlier than that of the onset of CMV infection/
isease (posttransplantation week 6). Thus, these
gents may have had little effect on the incidence of
HV-6 DNAemia. However, they possibly may have
ltered the clinical course of HHV-6 infection by
uppressing viral reactivation, which may have led us
o underestimate the clinical signiﬁcance of HHV-6
NAemia after allogeneic HSCT.
In the present study, 4 patients developed CNS
ymptoms during the study period. One patient was
iagnosed with bacterial meningitis, but the other 3
atients were diagnosed with HHV-6–associated
NS disorders. Diagnosis was based on positive re-
ults for HHV-6 DNA in CSF and the absence of
ther identiﬁed causes of CNS disorders. Although a
eﬁnition of CNS disorders associated with HHV-6
as yet to be established, CNS symptoms resolved
ompletely after initiating anti–HHV-6 therapy in 2
f our 3 patients, strongly suggesting the causative
ole of HHV-6 in CNS disorders in these patients. A
ossible reason for treatment failure in the 1 patient in
hom CNS symptoms did not resolve was the delay in
xamining CSF and the resulting delay in initiation of
ntiviral therapy. The patient was in serious condition
ue to severe acute GVHD, and CSF examination
ould not be performed in a timely manner. Weekly
onitoring was able to detect HHV-6 DNAemia at
he onset of CNS disorders; however, it was not able
o detect it before onset. Our experience suggests thatrompt examination of CSF is essential for the early
iagnosis and treatment of HHV-6–associated CNS
isorders, and that weekly HHV-6 DNAemia monitor-
ng could be a useful asset for diagnosing HHV-6–
ssociated CNS disorders. The small number of pa-
ients with HHV-6–associated CNS disorders makes
t difﬁcult to draw any deﬁnite conclusions. However,
HV-6 DNAemia monitoring may have less predic-
ive value, limiting the application of preemptive ther-
py using HHV-6 DNAemia for preventing HHV-6–
ssociated CNS disorders.
In the present study, we used real-time PCR to
uantitatively evaluate serial changes in HHV-6
NAemia early after allogeneic HSCT. In contrast
o the signiﬁcant difference in the incidence of
HV-6 DNAemia between CBT and BMT/
BSCT recipients, HHV-6 DNA levels did not
iffer signiﬁcantly between the 2 groups. The low
ncidence of HHV-6–associated CNS disorders (3
f 22 patients with HHV-6 DNAemia) makes it
ifﬁcult to statistically evaluate the effect of viral
oad on the development of HHV-6–associated
NS disorders. However, HHV-6–associated CNS
isorders developed in 2 of the 5 patients with
igh-level HHV-6 DNAemia ( 10,000 copies/mL)
ut in only 1 of 16 patients with low-level HHV-6
NAemia ( 10,000 copies/mL). Therefore, high-
evel HHV-6 DNAemia might be an important pa-
ameter for identifying patients at higher risk for
eveloping HHV-6–associated CNS disorders.
urther studies are needed to evaluate the relation-
hip between viral load and the development of
HV-6–associated CNS disorders.
We conclude that HHV-6 reactivation is fre-
uently observed after allogeneic HSCT, especially in
atients with some or all of the risk factors described
arlier. Together with the assessment of risk factors,
he monitoring of HHV-6 DNAemia could be a use-
ul tool for diagnosing HHV-6–associated CNS dis-
rders. Transplant physicians should be fully aware of
he possible occurrence of HHV-6–associated CNS
isorders in HSCT recipients who develop HHV-6
NAemia, as well as the importance of prompt exam-
nation to detect HHV-6 in CSF if such patients
evelop any CNS symptoms.
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